Early sensory neurophysiological changes in prediabetes

Yi-Chen Lin1,2, Cindy Shin-Yi Lin3,4, Tsui-San Chang1,2,5, Jing-Er Lee1,2, Jowy Tan1,2,3,6, Hung-Ju Chen1,2,5, Jia-Ying Sung1,2,5

INTRODUCTION

Diabetic neuropathies include distal symmetric polyneuropathy, chronic idiopathic sensory axonal neuropathy and small fiber neuropathy. The neurological complications of diabetes might arise as early as the time of diagnosis. Of all individuals with prediabetes, 11–25% have peripheral neuropathies. The possible mechanisms of axonal dysfunction, including disruption of Schwann cell metabolism, microvascular abnormalities and endothelial dysfunction through the polyol, hexosamine/protein kinase C, and advanced glycation end-product pathways, are related to hyperglycemia, dyslipidemia and insulin resistance. Hyperglycemia also causes excessive glycosylation, which overloads the mitochondria and causes excessive reactive oxygen species generation. Hexosamine pathway activation and extracellular advanced glycation end-product binding to receptors as a result of hyperglycemia might increase oxidative stress and trigger an inflammatory response. These phenomena of bioenergetic failure, osmotic and oxidative stress, and inflammation result in axonal dysfunction.

The nerve injury and metabolic derangement that occur in prediabetes patients might be reversible and transiently improved in the first year with diet control and exercise. Consequently, early diagnosis of neurological dysfunction is important for preventing neuropathic deterioration. Clinical practitioners urgently require a sensitive tool to detect early changes in nerves in diabetes and prediabetes patients. Many studies focusing on neuropathy in diabetes patients through traditional nerve conduction studies (NCSs) have been published, and the results show that NCSs are not a sensitive tool for diabetic polyneuropathies. In patients with prediabetes or impaired glucose tolerance, neuropathy predominantly involving small fibers was established to contribute to neuropathic pain, and autonomic dysfunction was established. Therefore, traditional NCSs, which are mainly for large nerve fibers, are
not sensitive enough to detect early nerve injury. This lack of sensitivity limits the clinical neurological assessment of polynuropathy in prediabetes or early diabetes patients.

In 1999, a nerve excitability test was developed to provide complementary information to traditional neurophysiological studies. This non-invasive test can provide clinical neurologists with nodal and paranodal ion channel activity levels, membrane potentials, and myelin properties in vivo. Kiernan et al. established a protocol measuring the “sensory” axonal nerve excitability, and confirmed its efficacy in studying the electrophysiology and channel function of sensory axons. Clinical application has been studied for different neurological diseases, such as cervical radiculopathy, cisplatin-induced neuropathy, uremic polyneuropathy and diabetic neuropathies. In previous nerve excitability tests among diabetes patients, the excitability parameters of sensory nerves changed earlier than those of motor nerves and were correlated with glycated hemoglobin (HbA1c) in individuals with asymptomatic diabetes. Therefore, a nerve excitability test could be an early tool for detecting neurophysiological changes in patients with hyperglycemia. The purpose of the present study was to use this tool to detect whether sensory axonal fiber changes begin in prediabetes and are associated with plasma glucose.

METHODS
Criteria for patient enrollment
A total of 40 patients (aged 42–80 years) at Wanfang Hospital (Taipei, Taiwan) who had been diagnosed with prediabetes were enrolled to undergo a nerve excitability test and an NCS. Prediabetes is defined by the American Diabetes Association as meeting one of the three following criteria: HbA1c of 5.7–6.4%, fasting glucose of 100–125 mg/dL or a result of 140–199 mg/dL on the 2-h oral glucose tolerance test. A total of 20 age-matched normoglycemic (NG) volunteers (aged 47–83 years) and 20 patients with diabetes (aged 42–70 years) were also enrolled. Diabetes was diagnosed according to the American Diabetes Association criteria, and the patients had received medical treatment. We excluded individuals with carpal tunnel syndrome, abnormal renal function (serum creatinine >1.2 mg/dL) and polyneuropathies caused by other etiologies.

The protocol for this research project was approved by a suitably constituted institutional ethics committee (TMU-Joint Institutional Review Board, Approval No. N201510049), and it conforms to the provisions of the Declaration of Helsinki.

Clinical evaluation
The enrolled patients underwent laboratory tests to determine their fasting plasma glucose, HbA1c and lipid profiles (total cholesterol, triglyceride and low-density lipoprotein cholesterol); additionally, their body mass index was calculated.

For the study of asymptomatic diabetes and prediabetes, we excluded patients with dysesthesia, hypoesthesia, numbness or weakness in their limbs. A neurological examination was also carried out. Furthermore, an NCS was performed on all participants in a neurophysiological laboratory at Wanfang Hospital, and the participants were required to have results within the normal ranges to be included in the study.

Nerve excitability test
Nerve excitability studies were carried out on all participants by stimulating the median nerve at the wrist according to TRONDNF protocols, with the skin temperature on the wrist maintained at ≥32.0°C. An isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, UK) provided the stimulus current. The changes in current required to produce a target potential corresponding to 50% of the maximal compound muscle action potential or sensory nerve action potential were tracked. Commercialized software (QTRAC version 10/11/2012; Institute of Neurology, London, UK) controlled the stimulation current and recorded the threshold changes.

The TRONDNF protocol was established by Kiernan et al. for the nerve excitability test. Four different electrostimulation tests were automatically carried out in the TRONDNF: (i) a test to establish the stimulus–response curve; (ii) a test to determine the strength–duration relationship, the rheobase and the strength–duration time constant (SDTC); (iii) a test to determine the threshold electrotonus (TE); that is, the potential change produced by 1-ms test pulses under 100-ms subthreshold conditioning; polarizing currents in both depolarizing (TEd) and hyperpolarizing (TEh) directions; and (iv) the recovery cycle, the threshold changes in response to a test stimulus pulse after a supramaximal conditioning stimulus with interstimulus intervals from 2 to 200 ms. The important parameters in the nerve excitability test include the SDTC, TEd, TEh, superfexitability and late subexcitability. SDTC is determined by nodal sodium permeability. TEd and TEh are determined mainly by internodal membrane properties and potential. Superexcitability is inhibited by paranodal fast potassium channel (Kf) function, and late subexcitability is determined by internodal slow potassium channel (Ks) function. Using these parameters, we can estimate the nodal and internodal function of the diseased axons.

Statistical analysis
We used Statistical Package for the Social Sciences (SPSS) for Windows version 21 (SPSS Inc., Chicago, IL, USA). Levene’s test for equality of variances was carried out on all variables. We compared the demographic profiles, nerve conduction results and nerve excitability parameters in the three groups by analysis of variance (ANOVA). We use Bonferroni’s method as a post-hoc test to analyze the pairwise differences between groups. Linear correlation was used to determine whether NCS and/or nerve excitability parameters were correlated with clinical profiles. We defined P-values ≤0.05 as significant.

RESULTS
Patient clinical profiles
The demographic and clinical features of the normoglycemic, prediabetic and diabetic cohorts are shown in Table 1. The
mean HbA1c levels were 5.30% in normoglycemia, 5.9% in prediabetes and 6.7% in diabetes ($P < 0.001$; Table 1). The mean fasting plasma glucose levels were 87.1 mg/dL in normoglycemia, 101.5 mg/dL in prediabetes and 128.75 mg/dL in diabetes ($P < 0.001$).

In addition to fasting plasma glucose, body mass index was higher in prediabetes than in normoglycemia (25.45 ± 4.05 vs 22.01 ± 2.33, $P = 0.003$). The NG cohort was noted to have higher total cholesterol than the prediabetes cohort (209.06 ± 35.16 mg/dL vs 176.49 ± 38.43 mg/dL, $P = 0.011$) or the diabetes cohort (175.21 ± 33.93 mg/dL, $P = 0.021$). The NG cohort had increased low-density lipoprotein cholesterol compared with the prediabetes cohort (132 ± 32.05 mg/dL vs 106.37 ± 34.70 mg/dL, $P = 0.024$). The difference in triglycerides among groups was not statistically significant (Table 1).

### Nerve conduction studies
All participants underwent NCS, the results of which are shown in Table 2. The results are within the normal range defined by the NCS laboratory at Wanfang Hospital.

### Nerve excitability test
Regarding the sensory axonal nerve excitability properties of participants with prediabetes, the superexcitability increased

---

**Table 1** | Demographic data and clinical profiles of the participants

| Clinical profile | Normoglycemia (n = 20) Mean (SD) | Prediabetes (n = 40) Mean (SD) | Diabetes (n = 20) Mean (SD) |
|------------------|---------------------------------|--------------------------------|-----------------------------|
| Male/female ($n$) | 10/10                           | 15/25                          | 13/7                        |
| Age (years)      | 62.35 (11.08)                   | 60.20 (9.14)                   | 57.55 (9.30)                |
| HbA1c (%)        | 5.3 (0.29)                      | 5.9 (0.23)                     | 6.7 (0.81)                  |
| Fasting plasma glucose (mg/dL) | 87.1 (5.96) | 101.5 (13.71) | 128.75 (31.76) |
| BMI (kg/m²)      | 22.01 (2.33)                    | 25.45 (4.05)                   | 23.44 (2.60)                |
| Cholesterol (mg/dL) | 209.06 (35.16) | 176.49 (38.23) | 175.21 (33.93) |
| LDL (mg/dL)      | 132 (32.05)                     | 106.37 (34.70)                 | 106.74 (25.96)              |
| Triglycerides (mg/dL) | 99.05 (40.85) | 108.86 (49.17) | 137.99 (41.05) |

---

**Table 2** | Comparison of sensory nerve neurophysiology studies in participants with normoglycemia, prediabetes and diabetes

| Nerve excitability tests | Normoglycemia Mean (SD) | Prediabetes Mean (SD) | Diabetes Mean (SD) |
|-------------------------|--------------------------|-----------------------|--------------------|
| Latency (ms)            | 3.12 (0.29)              | 3.23 (0.38)           | 3.45 (0.43)        |
| SDTC                    | 0.58 (0.13)              | 0.56 (0.13)           | 0.52 (0.09)        |
| Superexcitability (%)   | −19.09 (4.56)            | −22.39 (3.16)         | −23.71 (5.15)      |
| Subexcitability (%)     | 11.12 (2.97)             | 11.26 (2.58)          | 10.30 (2.65)       |
| RRP (ms)                | 3.34 (0.62)              | 3.18 (0.40)           | 3.15 (0.48)        |
| Refractoriness (%)      | 20.26 (19.53)            | 16.32 (15.58)         | 10.49 (14.91)      |
| TEh (90–100 ms)         | −149.23 (19.69)          | −149.27 (20.40)       | −152.66 (26.77)    |

The skin temperature at the wrist was maintained at ≥32.0°C for all studies. 

---

The normal ranges defined by the nerve conduction study laboratory at Taipei Municipal Wanfang Hospital: median distal sensory latency <2.8 ms, median sensory nerve action potential (SNAP) amplitude >10 μV, median sensory nerve conduction velocity (NCV) 48.7–65.5 m/s, sural SNAP amplitude >5 μV, sural NCV: 41.5–58.3 m/s. CMAP, compound muscle action potential; RRP, relative refractory period; SDTC, strength-duration time constant; TEh, threshold electrotonus in hyperpolarization.

---

The skin temperature at the wrist was maintained at ≥32.0°C for all studies. 

---

The normal ranges defined by the nerve conduction study laboratory at Taipei Municipal Wanfang Hospital: median distal sensory latency <2.8 ms, median sensory nerve action potential (SNAP) amplitude >10 μV, median sensory nerve conduction velocity (NCV) 48.7–65.5 m/s, sural SNAP amplitude >5 μV, sural NCV: 41.5–58.3 m/s. CMAP, compound muscle action potential; RRP, relative refractory period; SDTC, strength-duration time constant; TEh, threshold electrotonus in hyperpolarization.
significantly (−22.39 ± 3.16% in prediabetes and −19.09 ± 4.56% in NG, P = 0.013; Figures 1d,2b; Table 2). The participants with diabetes had greater superexcitability than the NG participants (−23.71 ± 5.15%, P = 0.002, Figures 1d,2b; Table 2). The latencies in prediabetes and diabetes were mildly prolonged, but the only significant difference was between diabetes and normoglycemia (Figure 2a). There was no difference among the three cohorts in other parameters: SDTC (Figure 1b; Table 2), subexcitability, refractoriness (%), relative refractory period (Figure 1d; Table 2) and TE (Figure 1c; Table 2).

Correlations between axonal excitability parameters and clinical profiles
The sensory superexcitability of all enrolled participants was positively correlated with both fasting plasma glucose (correlation coefficient 0.291, P = 0.009) and HbA1c levels (correlation coefficient 0.331, P = 0.003; Figure 3). All measured parameters, including other NCS and nerve excitability parameters, were uncorrelated with plasma fasting glucose, HbA1c and lipid profiles. The linear regression implied that plasma fasting glucose and HbA1c were more important than other metabolic factors including body mass index, bodyweight, total cholesterol, low-density lipoprotein, and triglyceride level in determining sensory axonal function (superexcitability).

DISCUSSION
The present results showed that sensory superexcitability increased in prediabetes and diabetes patients. Superexcitability is determined by the membrane potential or the function of the paranodal $K_f$ channel. Two main factors increase superexcitability: the hyperpolarization of membrane potential and a decrease in $K_f$ function.$^{16,17,29}$ Membrane hyperpolarization might not be the cause in prediabetes, because no changes of parameters, such as increased threshold current, reduced the SDTC, increase in TE and reduced subexcitability, were found.$^{30,31}$ Therefore, we assumed the change of superexcitability was a result of $K_f$ channel dysfunction. Calvo et al.$^{33}$ documented that expression of fast potassium channels (including Kv1.1 and Kv1.2) at juxtaparanodal region is markedly reduced in the injured sensory axon animal model. In addition, axonal hyperexcitability and increasing spontaneous discharge occurred. Zenker et al.$^{34}$ found reduced presence of the

Figure 1 | (a) The peak response showed a similar threshold in all three groups. (b) There was no difference in the strength-duration time constant (SDTC) between the three groups. (c) The threshold electrotonus did not show a fanning-out pattern in depolarizing or hyperpolarizing conditions. (d) The recovery cycle showed increased superexcitability in the prediabetes and asymptomatic diabetes groups compared with the normoglycemic group. However, there was no difference in subexcitability, refractoriness or relative refractory period among the three groups. Blue line: normoglycemia; green line: prediabetes; red line: asymptomatic diabetes.
Kv1.2 in juxtaparanodal regions of axons in both a type 2 diabetes animal model and in human peroneal nerve biopsy samples. These studies imply fast potassium channel dysfunction plays an important role in sensory axonal hyperexcitability. Therefore, we surmised that the increased superexcitability in prediabetes is related to the reduction in $K_f$ function. In Figure 4, we showed the possible neurophysiological changes in prediabetic axons. Hyperglycemia causes intracellular sorbitol accumulation and affects mitochondrial function. These alterations lead to increasing metabolic stress and energy failure. Consequently, the Na$^+$/K$^+$ pump will be hypoactive, reducing both the sodium and potassium gradients across the axonal membrane. The reduced ion gradients will also decrease paranodal $K_f$ function. The metabolic change is mild in prediabetes patients; therefore, the membrane potential might not be affected. Other nerve excitability parameters are not different from those in individuals with NG.

Misawa et al. reported that reduced activation of paranodal $K_f$ conductance is related to increased superexcitability in hyperglycemia. Kitano et al. also reported that reduced SDTC in diabetes reduced nodal Na$^+$ conductance. Those discoveries suggest that the pathogenesis of diabetic neuropathy starts from nodal and paranodal impairment. Consequently, we hypothesized that changes in prediabetic nerve function might also start in the paranodal area. Superexcitability is the most sensitive parameter for paranodal ion conductance changes; this finding is compatible with the present results for increasing superexcitability, which is the earliest change in prediabetes.

In the present study, sensory axonal superexcitability tended to increase with normoglycemia, prediabetes and diabetes. These changes were not affected by acute plasma glucose concentration, but were related to glycemic variability. Our previous study also reported downward shifting of the sensory
recovery cycle and “fanning out” of TE progress from asymptomatic to symptomatic diabetes. These findings suggest functional changes precede structural changes in diabetes polyneuropathy; they can also explain why the NCS is not a sensitive tool for clinical detection or screening. The results of the present study suggest that preventing the progression of neuropathy should start at the beginning of glucose instability.

In the present study, none of the patients or healthy controls had any symptoms or signs of neuropathy. Slight changes in sensory nerve excitability were detected in patients with asymptomatic prediabetes, indicating the start of axonal changes. As observed in epidemiological and some skin biopsy studies, injury to the peripheral nerves might start in the prediabetic stage. We suspect that the possible pathogenesis is the same in prediabetes patients and early diabetes patients without neuropathy. Animal model studies also support the view that the pathophysiology of peripheral nerve dysfunction in patients with prediabetes or metabolic syndrome is similar to that in early diabetes patients without structural or pathological changes.

We found that sensory superexcitability was positively correlated with fasting plasma glucose and HbA1c in all participants. Similar correlations between nerve excitability parameters (superexcitability and late subexcitability) and clinical profiles have been discovered in diabetes patients. However, aggressive glycemic control is an effective approach to reduce the risk of polyneuropathy only in type 1 diabetes patients. A possible explanation is that complicated metabolic and inflammatory factors contribute to neuropathy in long-term type 2 diabetes.

In the present study, the correlation of HbA1c with sensory hyperexcitability suggests that glucose control in prediabetes or the early stage of diabetes might slow the deterioration of axonal function. However, this hypothesis requires further empirical support.

**Figure 4**

1. Hyperglycemia, hyperlipidemia and advanced glycation end-products lead to sorbitol accumulation through the polyol pathway; 2. increased metabolic stress, and induce anaerobic metabolism and energy failure with decreased adenosine triphosphate (ATP) production; resulting in 3. Na⁺/K⁺ pump dysfunction; which 4. reduces the transmembrane concentration gradients of both sodium and potassium; consequently, there is 5. a decrease in potassium conductance by hypoactive Kᵢ channels, resulting in increased superexcitability.
In prediabetes, peripheral nerve dysfunction might be reversed if environmental factors are corrected. Kitano et al. reported that superexcitability shifted toward a normal range after the start of insulin treatment for diabetes. In a prediabetic animal model, the administration of an aldose reductase inhibitor corrected the peripheral neurological dysfunction induced by a high-fat diet. In addition, lifestyle intervention, including diet control and exercise in patients with impaired glucose tolerance, results in restoration of cutaneous nerve endings and improvement of neuropathic pain. We believe that the physiological changes might be reversed in the prediabetic and early diabetic stages, which is the reason why we focus on prediabetes rather than diabetes patients.

In conclusion, we believe that physiological changes in nerves begin to arise in the prediabetic stage, and that the Na+/K+ pumps are hypoactive caused by metabolic changes after hyperglycemia. In prediabetes patients, sensory axons are more vulnerable than motor axons, and the nerve excitability parameter that is most sensitive to hyperglycemia is superexcitability. Sensory axonal superexcitability is the most sensitive parameter in preclinical neurophysiological dysfunction in prediabetes. The present results show that sensory axonal superexcitability has a significantly positive correlation with fasting plasma glucose and HbA1c. Sensory nerve excitability provides a non-invasive tool for early detection to prevent the progression of diabetic neuropathy.

ACKNOWLEDGMENTS
This study is financially supported by Taipei Municipal Wanfang Hospital (WFH), Taipei Medical University, and the Ministry of Science and Technology (MOST), Taipei, Taiwan. The grant numbers are 105-wf-eva-26, 108-wf-eva-20 (WFH) and MOST104-2314-B-038-012-1-3 (MOST).

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Papanas N, Vnik Al, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7: 682–690.
2. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521–534.
3. Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 2017; 93: 1296–1313.
4. Goncalves NP, Vaegter CB, Andersen H, et al. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol 2017; 13: 135–147.
5. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29: 1294–1299.
6. Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 2011; 44: 340–345.
7. Dyck PJ, Kratz KM, Kames JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817–824.
8. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46(Suppl 2): S54–S57.
9. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist 2008; 14: 23–29.
10. Smith AGR, Ramachandran P, Tripp S, et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001; 57: 1701–1704.
11. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig 2017; 8: 646–655.
12. Sumner CJS, Sheth S, Griffin JI, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108–111.
13. Dyck PJ, Clark VM, Overland CJ, et al. Impaired glycermia and diabetic polyneuropathy: the OC IG Survey. Diabetes Care 2012; 35: 584–591.
14. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21: 137–158.
15. Kieman MC, Burke D, Andersen KV, et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23: 399–409.
16. Kieman MC, Bostock H, Park SB, et al. Measurement of axonal excitability: consensus guidelines. Clin Neurophysiol 2019. https://doi.org/10.1016/j.clinph.2019.07.023
17. Kieman MC, Lin CS, Andersen KV, et al. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001; 24: 883–892.
18. Sung JY, Tani J, Hung KS, et al. Sensory axonal dysfunction in cervical radiculopathy. J Neurol Neurosurg Psychiatry 2015; 86: 640–645.
19. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009; 132: 2712–2723.
20. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16: 708–716.
21. Park SB, Lin CS, Krishnan AV, et al. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS ONE 2011; 6: e18469.
22. Krishnan AV, Phoon RK, Pussell BA, et al. Altered motor nerve excitability in end-stage kidney disease. Brain 2005; 128: 2164–2174.
23. Krishnan AV, Phoon RK, Pussell BA, et al. Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 2006; 77: 548–551.

24. Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005; 128: 1178–1187.

25. Sung JY, Park SB, Liu YT, et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes 2012; 61: 1592–1598.

26. Sung JY, Tani J, Chang TS, et al. Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS ONE 2017; 12: e0171223.

27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62–S69.

28. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 2018; 41: S13–S27.

29. Nodera H, Kaji R. Nerve excitability testing and its clinical application to neuromuscular diseases. Clin Neurophysiol 2006; 117: 1902–1916.

30. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123(Pt 12): 2542–2551.

31. Krishnan AV, Lin CS, Park SB, et al. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol 2009; 89: 288–313.

32. Calvo M, Richards N, Schmid AB, et al. Altered potassium channel distribution and composition in myelinated axons suppresses hyperexcitability following injury. Elife 2016; 5: e12661.

33. Zenker J, Poiriot O, de Preux Charles AS, et al. Altered distribution of juxtaparanodal Kv1.2 subunits mediates peripheral nerve hyperexcitability in type 2 diabetes mellitus. J Neurosci 2012; 32: 7493–7498.

34. Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 2014; 17: 153–163.

35. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599–606.

36. Misawa S, Kuwabara S, Kanai K, et al. Axonal potassium conductance and glycemic control in human diabetic nerves. Clin Neurophysiol 2005; 116: 1181–1187.

37. Sima AA. Metabolic alterations of peripheral nerve in diabetes. Semin Neurol 1996; 16: 129–137.

38. Misawa S, Kuwabara S, Ogawara K, et al. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol 2005; 116: 254–258.

39. Kitano Y, Kuoabara S, Misawa S, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 2004; 56: 462–467.

40. Kwai NC, Arnold R, Poynten AM, et al. Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle Nerve 2016; 54: 967–969.

41. Ziegler DR, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009; 10: 393–400.

42. Davidson EP, Coppey LJ, Calcutt NA, et al. Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev 2010; 26: 306–318.

43. Groover AL, Ryals JM, Guilford BL, et al. Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 2013; 154: 2658–2667.

44. Obrosova IG, Illytska O, Lysogubov VV, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition. Diabetes 2007; 56: 2598–2608.